ArticleBiomolecules & therapeutics2016
Pharmacokinetic Interaction of Chrysin with Caffeine in Rats.
Article in Biomolecules & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Cardiovascular protective effects of natural flavonoids on intestinal barrier injury.Molecular and cellular biochemistry · 2025Review
- Poly lactic-co-glycolic acid enhances the efficacy of the phytomedicine chrysin against cisplatin induced toxicity in submandibular salivary glands.Scientific reports · 2025Article
- 5,7-Dihydroxyflavone acts on eNOS to achieve hypotensive effects in spontaneously hypertensive rats.Scientific reports · 2025Article
- Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective.Exploration of targeted anti-tumor therapy · 2024Review
- Cardiorespiratory and Neuroprotective Effects of Caffeine in Neonate Animal Models.Animals : an open access journal from MDPI · 2023Review
- Trained immunity in monocyte/macrophage: Novel mechanism of phytochemicals in the treatment of atherosclerotic cardiovascular disease.Frontiers in pharmacology · 2023Review
- Anticancer potential of phytochemicals fromToxicology reports · 2023Article
- Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Regulation of Nrf2/ARE Pathway by Dietary Flavonoids: A Friend or Foe for Cancer Management?Antioxidants (Basel, Switzerland) · 2020Review
- Herbal Medicinal Products fromTheScientificWorldJournal · 2020Review
- Pharmacokinetics of B-Ring Unsubstituted Flavones.Pharmaceutics · 2019Review
- Calculation of a First-In-Man Dose of 7-Biomolecules & therapeutics · 2017Article
- Halogenated Chrysins Inhibit Dengue and Zika Virus Infectivity.Scientific reports · 2017Article
- Low-Dose Bisphenol A Increases Bile Duct Proliferation in Juvenile Rats: A Possible Evidence for Risk of Liver Cancer in the Exposed Population?Biomolecules & therapeutics · 2017Article
- Measurement of caffeine and its three primary metabolites in human plasma by HPLC-ESI-MS/MS and clinical application.Biomedical chromatography : BMC · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacokinetic interaction of chrysin, a flavone present in honey, propolis and herbs, with caffeine was investigated in male Sprague-Dawley rats. Because chrysin inhibited CYP1A-selective ethoxyresorufin O-deethylase and methoxyresorufin O-demethylase activities in enriched rat liver microsomes, the pharmacokinetics of caffeine, a CYP 1A substrate, was studied following an intragastric administration with 100 mg/kg chrysin. In addition to the oral bioavailability of chrysin, its phase 2 metabolites, chrysin sulfate and chrysin glucuronide, were determined in rat plasma. As results, the pharmacokinetic parameters for caffeine and its three metabolites (i.e., paraxanthine, theobromine and theophylline) were not changed following chrysin treatment in vivo, despite of its inhibitory effect on CYP 1A in vitro. The bioavailability of chrysin was found to be almost zero, because chrysin was rapidly metabolized to its sulfate and glucuronide conjugates in rats. Taken together, it was concluded that the little interaction of chrysin with caffeine might be resulted from the rapid metabolism of chrysin to its phase 2 metabolites which would not have inhibitory effects on CYP enzymes responsible for caffeine metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.